{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:44:17Z","timestamp":1792601057669,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:00:00Z","timestamp":1770508800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism Open"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.metop.2026.100449","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T08:17:17Z","timestamp":1770625037000},"page":"100449","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["GLP-1 receptor agonists and obstructive lung disease: Beyond metabolic control to respiratory outcomes"],"prefix":"10.1016","volume":"29","author":[{"given":"Vasiliki Epameinondas","family":"Georgakopoulou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7008-388X","authenticated-orcid":false,"given":"Maria","family":"Dalamaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.metop.2026.100449_bib1","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S2213-2600(24)00339-4","article-title":"The global burden of COPD: epidemiology and effect of prevention strategies","volume":"13","author":"de Oca","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"12","key":"10.1016\/j.metop.2026.100449_bib2","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.46598","article-title":"Global Burden of Chronic Obstructive Pulmonary Disease Through 2050","volume":"6","author":"Boers","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.metop.2026.100449_bib3","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S2213-2600(25)00003-7","article-title":"Asthma and allergic diseases collaborators. Global, regional, and national burden of asthma and atopic dermatitis, 1990-2021, and projections to 2050: a systematic analysis of the global burden of Disease Study 2021","volume":"13","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.metop.2026.100449_bib4","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-069679","article-title":"Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990-2019: results from the global burden of disease study 2019","volume":"378","author":"Safiri","year":"2022","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.metop.2026.100449_bib5","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.3390\/jcm14061809","article-title":"Chronic obstructive pulmonary disease and type 2 diabetes mellitus: complex interactions and clinical implications","volume":"14","author":"Anghel","year":"2025","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.metop.2026.100449_bib6","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1136\/thorax-2024-222819","article-title":"Association between asthma and type 2 diabetes in a Swedish adult population: a register-based cross-sectional study","volume":"80","author":"Mubanga","year":"2025","journal-title":"Thorax"},{"issue":"12","key":"10.1016\/j.metop.2026.100449_bib7","first-page":"e5043","article-title":"Asthma in youth and early-onset type 2 diabetes: a nationwide study of 1.72 million Israeli adolescents","volume":"106","author":"Shapiro","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.metop.2026.100449_bib8","article-title":"Metabolic syndrome, small airway dysfunction and the mediating role of inflammation","volume":"15","author":"Xie","year":"2025","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.metop.2026.100449_bib9","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.chest.2016.08.1432","article-title":"Obesity is associated with increased morbidity in moderate to severe COPD","volume":"151","author":"Lambert","year":"2017","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.metop.2026.100449_bib10","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1016\/j.jaip.2019.02.029","article-title":"Association between prediabetes\/diabetes and asthma exacerbations in a claims-based Obese asthma cohort","volume":"7","author":"Wu","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.metop.2026.100449_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-071380","article-title":"Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: population based cohort study","volume":"379","author":"Pradhan","year":"2022","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.metop.2026.100449_bib12","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/jamainternmed.2024.7811","article-title":"Glucose-lowering medications and risk of chronic obstructive pulmonary disease exacerbations in patients with type 2 diabetes","volume":"185","author":"Ray","year":"2025","journal-title":"JAMA Intern Med"},{"issue":"11","key":"10.1016\/j.metop.2026.100449_bib13","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1136\/thorax-2023-221040","article-title":"Glucagon-like peptide-1 receptor agonists May benefit cardiopulmonary outcomes in patients with COPD","volume":"79","author":"Yen","year":"2024","journal-title":"Thorax"},{"issue":"6","key":"10.1016\/j.metop.2026.100449_bib14","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.2337\/dc20-1794","article-title":"Glucagon-like peptide 1 receptor agonists and chronic lower respiratory disease exacerbations among patients with type 2 diabetes","volume":"44","author":"Albogami","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metop.2026.100449_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2025.108197","article-title":"Glucagon-like peptide 1 (GLP-1) receptor agonists and asthma and COPD exacerbations in adults with diabetes: a systematic review","volume":"245","author":"Cooper","year":"2025","journal-title":"Respir Med"},{"issue":"9","key":"10.1016\/j.metop.2026.100449_bib16","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.3390\/ph18091337","article-title":"Efficacy of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on moderate-to-severe COPD exacerbations among patients with type 2 diabetes: a systematic review and network meta-analysis","volume":"18","author":"Pirera","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.metop.2026.100449_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2025.1721311","article-title":"Novel antidiabetic agents and the risk of respiratory diseases: a systematic review and meta-analysis of 27 randomized controlled trials","volume":"12","author":"Yu","year":"2026","journal-title":"Front Med"},{"key":"10.1016\/j.metop.2026.100449_bib18","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2147\/COPD.S350133","article-title":"Respiratory effects of treatment with a glucagon-like Peptide-1 receptor agonist in patients suffering from obesity and chronic obstructive pulmonary disease","volume":"17","author":"Altintas Dogan","year":"2022","journal-title":"Int J Chronic Obstr Pulm Dis"},{"key":"10.1016\/j.metop.2026.100449_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103332","article-title":"Frailty-stratified effectiveness of SGLT2 inhibitors versus DPP-4 inhibitors and GLP-1 receptor agonists on pulmonary outcomes in type 2 diabetes: a nationwide cohort study","volume":"85","author":"Meng","year":"2025","journal-title":"eClinicalMedicine"},{"issue":"1","key":"10.1016\/j.metop.2026.100449_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-19657-5","article-title":"Association between glucagon-like peptide-1 receptor agonist therapy and respiratory illness in patients with type 2 diabetes: a retrospective observational cohort study","volume":"15","author":"Ho","year":"2025","journal-title":"Sci Rep"},{"issue":"7","key":"10.1016\/j.metop.2026.100449_bib21","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1164\/rccm.202004-0993OC","article-title":"Asthma exacerbations in patients with type 2 diabetes and asthma on glucagon-like Peptide-1 receptor agonists","volume":"203","author":"Foer","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.metop.2026.100449_bib22","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1001\/jamainternmed.2024.5982","article-title":"Antidiabetic medication and asthma attacks","volume":"185","author":"Lee","year":"2025","journal-title":"JAMA Intern Med"},{"issue":"11","key":"10.1016\/j.metop.2026.100449_bib23","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1513\/AnnalsATS.202309-836OC","article-title":"Glucagon-like peptide 1 receptor agonists and asthma exacerbations: which patients benefit Most?","volume":"21","author":"Wang","year":"2024","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.metop.2026.100449_bib24","first-page":"A237","article-title":"P158 the association between GLP-1 receptor agonist use and mortality among COPD patients","volume":"80","author":"Alaws","year":"2025","journal-title":"Thorax"},{"issue":"11","key":"10.1016\/j.metop.2026.100449_bib25","doi-asserted-by":"crossref","DOI":"10.1177\/03000605251392717","article-title":"Unraveling the obesity-asthma link: a new horizon with glucagon-like peptide-1 receptor agonists in a complex intersection of metabolism and airway disease","volume":"53","author":"Menzella","year":"2025","journal-title":"J Int Med Res"},{"key":"10.1016\/j.metop.2026.100449_bib26","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2147\/COPD.S393323","article-title":"The role of glucagon-like Peptide-1 receptor agonists in chronic obstructive pulmonary disease","volume":"18","author":"Wang","year":"2023","journal-title":"Int J Chronic Obstr Pulm Dis"},{"issue":"3","key":"10.1016\/j.metop.2026.100449_bib27","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/cea.12860","article-title":"Glucagon-like peptide-1 receptor expression on human eosinophils and its regulation of eosinophil activation","volume":"47","author":"Mitchell","year":"2017","journal-title":"Clin Exp Allergy"},{"issue":"4","key":"10.1016\/j.metop.2026.100449_bib28","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology"},{"issue":"21","key":"10.1016\/j.metop.2026.100449_bib29","doi-asserted-by":"crossref","DOI":"10.1172\/JCI194751","article-title":"Antiinflammatory actions of glucagon-like peptide-1-based therapies beyond metabolic benefits","volume":"135","author":"Wong","year":"2025","journal-title":"J Clin Investig"},{"issue":"1","key":"10.1016\/j.metop.2026.100449_bib30","doi-asserted-by":"crossref","first-page":"929","DOI":"10.3892\/mmr.2017.6618","article-title":"Overexpression of GLP-1 receptors suppresses proliferation and cytokine release by airway smooth muscle cells of patients with chronic obstructive pulmonary disease via activation of ABCA1","volume":"16","author":"Sun","year":"2017","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.metop.2026.100449_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111894","article-title":"Preventing CXCL12 elevation helps to reduce acute exacerbation of COPD in individuals co-existing type-2 diabetes: a bioinformatics and clinical pharmacology study","volume":"132","author":"Xue","year":"2024","journal-title":"Int Immunopharmacol"},{"issue":"10296","key":"10.1016\/j.metop.2026.100449_bib32","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications","volume":"398","author":"Brown","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.metop.2026.100449_bib33","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ajcnut.2025.04.023","article-title":"Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American college of lifestyle medicine, the American society for nutrition, the obesity medicine association, and the obesity society","volume":"122","author":"Mozaffarian","year":"2025","journal-title":"Am J Clin Nutr"},{"issue":"12","key":"10.1016\/j.metop.2026.100449_bib34","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1080\/02770903.2024.2372600","article-title":"Can glucagon-like peptide-1 receptor agonists induce asthma? An analysis of the FAERS database","volume":"61","author":"Cazzola","year":"2024","journal-title":"J Asthma"},{"issue":"1","key":"10.1016\/j.metop.2026.100449_bib35","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/ACI.0000000000000797","article-title":"Evaluating the glucagon-like peptide-1 receptor in managing asthma","volume":"22","author":"Wu","year":"2022","journal-title":"Curr Opin Allergy Clin Immunol"}],"container-title":["Metabolism Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589936826000083?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589936826000083?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T18:04:31Z","timestamp":1775757871000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589936826000083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":35,"alternative-id":["S2589936826000083"],"URL":"https:\/\/doi.org\/10.1016\/j.metop.2026.100449","relation":{},"ISSN":["2589-9368"],"issn-type":[{"value":"2589-9368","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GLP-1 receptor agonists and obstructive lung disease: Beyond metabolic control to respiratory outcomes","name":"articletitle","label":"Article Title"},{"value":"Metabolism Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metop.2026.100449","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100449"}}